6533b81ffe1ef96bd1278539
RESEARCH PRODUCT
Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?
Juan SanchisJulio NúñezAntoni Bayes-genisRafael De La Espriellasubject
Clinical PracticeAtherogenic dyslipidemiaInsulin resistancebusiness.industryMetabolic effectsHeart failuremedicineCardiology and Cardiovascular Medicinemedicine.diseaseBioinformaticsbusinessObesitySacubitril Valsartandescription
The burden of cardiometabolic diseases continues to rise worldwide (1). Obesity, insulin resistance, atherogenic dyslipidemia, hypertension and intra-abdominal adiposity are strongly interrelated and are crucial determinants of heart failure (HF) (2).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-08-01 | Cardiovascular Diagnosis and Therapy |